Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial. The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results, the trial met its primary target of reducing the risk of cancer recurrence and its secondary target of reducing the risk of cancer spreading to other parts of the body...